Ori Biotech Partners With Europlaz on IRO Supply
Essex-based contract manufacturer Europlaz will supply Ori Biotech's GMP-ready IRO consumables to cell and gene therapy developers worldwide.
Updated on Nov. 18, 2026 in Biotech

Ori Biotech has partnered with Europlaz, an Essex-based medical contract manufacturer, to supply its GMP-ready IRO consumable family to cell and gene therapy developers worldwide. The two companies have worked together since 2023, when Europlaz began providing development and design for manufacturing services to Ori.
Why it matters
Demand is growing from academic medical centres, CDMOs, and biopharma companies moving cell therapy programmes toward approval and commercial scale. Recent consumable shortages elsewhere in the industry have shown how supply chain risk can derail development timelines and commercial launch readiness.
IRO consumables are clean injection moulded and clean assembled in an ISO 7 cleanroom under a quality management system. The announcement does not state production volumes, capacity targets, or the timeline for scaling output.
The players
Ori Biotech
Ori Biotech is a company with bases in London and Philadelphia that develops and supplies consumables for cell and gene therapy manufacturing.
Europlaz
Europlaz is an Essex-based medical contract manufacturer that provides development, design for manufacturing, and cleanroom production services.
The details
Europlaz will provide dedicated cleanroom space, equipment access, material holding, and inventory management to Ori Biotech. Ori operates from bases in London and Philadelphia and is supplying its IRO consumable family to developers across international markets.
Timeline
2023: Europlaz began development and design for manufacturing services for Ori Biotech.
2026: Ori Biotech signed several new partnerships, including the arrangement with Europlaz.
The Tech Race
The arrangement extends GMP-grade, ISO 7 cleanroom consumable production into a shared contract-manufacturing model, a direction the cell and gene therapy field is pursuing as programmes move toward commercial scale. It positions Ori against competitors that must also secure reliable consumable supply for their customers.
For cell and gene therapy developers, reliable access to GMP-ready consumables can determine whether development timelines hold. The partnership aims to reduce the supply risk that has delayed programmes elsewhere in the industry.
The takeaway
Supply reliability is becoming a central factor in whether cell and gene therapies reach patients, so developers should evaluate their consumable sourcing early in planning. Partnerships that pair manufacturing capacity with inventory management can reduce the risk of costly delays.
Further reading
For more on how manufacturing advances are reshaping treatment development, explore Biotech coverage.
Source note: This article includes information reported by Insider Media Ltd.



